🔹 Revenue: $23.74B (Est. $22.86B) 🟢; +5.8% YoY
🔹 Adj. EPS: $2.77 (Est. $2.68) 🟢; -1.8% YoY
FY25 Guidance
🔹 Reported Sales: $93.2B–$93.6B (Est. $91.3B) 🟢
🔹 Adj. EPS: $10.63–$10.73 (Est. $10.61) 🟢; +7.0% YoY
🔹 Adj. Oper Revenue Growth: +3.2% to +3.7% (Prior: +2.0% to +3.0%)
🔹 Operational Sales: $92.7B–$93.1B (Prior: $91.6B–$92.4B)
Segment Revenue
🔹 Innovative Medicine: +2.4% YoY
🔹 MedTech: +4.1% YoY
Regional Revenue (Adjusted Operational)
🔹 U.S.: +5.0% YoY
🔹 International: +0.4% YoY
Other Q2 Metrics:
🔹 Net Income: $5.54B; +18.2% YoY
🔹 Adjusted Operational Sales: +3.0% YoY
🔹 Free Cash Flow: ~$6.2B
CEO Commentary
🔸 “Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business.”
🔸 “Our portfolio and pipeline position us for elevated growth in the second half of the year with game-changing approvals and submissions.”